** German drug containment and delivery systems maker Schott Pharma 1SXP.DE is upgraded to "buy" from "neutral" by UBS, which says two headwinds are abating
** The analyst expects the sector-wide vial destocking following the COVID pandemic to abate by mid 2025 at the latest noting positive developments in order intake
** Following last year's order cancellations the broker removes about EUR 90 million of mRNA polymer syringe sales from its estimates
** However, UBS still sees potential for growth in the glass syringe business on the back of capacity additions to more than offset the reduction in mRNA polymer syringe sales
** UBS says Schott trades at about a 30% discount to peer Stevanato STVN.N despite similar sales and profits three year compounded annual growth rates
** Out of 12 analysts that cover SCHOTT Pharma AG & Co KgaA, five rate the stock "strong buy" or "buy," four rate "hold" and three rate the stock "strong sell" or "sell"
(Reporting by Simon Ferdinand Eibach)
((Simonferdinand.eibach@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。